Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Gene Panels - Global Strategic Business Report 2026: Capitalize on 17.9% CAGR as Market Triples to $12.6B by 2032 - Track Key Players Illumina, Roche, QIAGEN, Thermo Fisher, Agilent and More

globenewswire.com
ILMN Illumina is mentioned as a key player in the global gene panel market, which is projected to experience significant growth. The article does not provide specific sentiment towards Illumina's performance or prospects. QGEN QIAGEN is identified as a key participant in the global gene panel market, which is expected to grow substantially. The article does not offer specific sentiment or analysis regarding QIAGEN's performance or outlook. TMO Thermo Fisher Scientific is named as a key company in the global gene panel market, which is projected for strong growth. The article does not provide specific sentiment or details about Thermo Fisher's role or performance within this market. AGNC Agilent is mentioned as a key player in the global gene panel market, which is forecast to grow significantly. The article does not provide specific sentiment or analysis related to Agilent's business or market position.

Gene Panels - Global Strategic Business Report 2026: Capitalize on 17.9% CAGR as Market Triples to $12.6B by 2032 - Track Key Players Illumina, Roche, QIAGEN, Thermo Fisher, Agilent and More Dublin, Nov. 10, 2026 (GLOBE NEWSWIRE) -- "Gene Panel - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering.

The global gene panel market, valued at US$4 billion in 2025, is projected to reach US$12.6 billion by 2032, expanding at a compound annual growth rate (CAGR) of 17.9%. Market growth is being supported by advances in next-generation sequencing (NGS), increasing adoption of personalized medicine, rising demand for early disease detection and the growing prevalence of cancer, cardiovascular conditions, neurological disorders and hereditary diseases.

Gene panels have become integral to genomic medicine because they enable targeted analysis of disease-associated genes. Their expanding role in oncology, cardiology, neurology, reproductive health and rare disease research is improving diagnostic accuracy and helping healthcare professionals select treatments aligned with individual genetic profiles.

Next-Generation Sequencing Strengthens Gene Panel Performance

NGS technology continues to transform the gene panel market by enabling simultaneous analysis of multiple genes with greater speed, scalability and cost efficiency. This capability is accelerating the integration of gene panels into clinical diagnostics and biomedical research while broadening access to genomic testing.

Advances in bioinformatics are also improving the interpretation of sequencing data. Modern analytical platforms support pathogenic variant identification, benign variant filtering and clinical significance assessment. Cloud-based systems further streamline data storage, analysis and collaboration across diagnostic laboratories, healthcare organizations and research institutions.

Custom gene panel development represents another important area of innovation. Panels can be configured around patient symptoms, family history, disease risk or emerging biomarkers. This flexibility is particularly valuable in rare disease investigation and complex cases requiring focused analysis of uncommon genetic variants.

Personalized Medicine and Early Detection Drive Adoption

Demand for gene panels is rising as healthcare systems adopt more individualized diagnostic and treatment strategies. In oncology, panels can identify clinically relevant mutations such as EGFR in lung cancer, KRAS in colorectal cancer and BRCA1 or BRCA2 in hereditary breast and ovarian cancer. These findings can support therapy selection, risk assessment, enhanced surveillance and preventive intervention.

Gene panels are also increasingly used to detect inherited cardiovascular conditions, including hypertrophic cardiomyopathy and arrhythmogenic cardiomyopathy. Prenatal and preconception applications can identify carrier status and inherited disease risks, supporting informed reproductive planning and earlier clinical preparation.

Additional market momentum is coming from regulatory approvals, greater public awareness of genetic testing and the expansion of direct-to-consumer services. As genomic information becomes more closely integrated with routine care, gene panels are expected to play a larger role in disease prevention, diagnosis, prognosis and treatment selection.

Market Segment and Regional Outlook

The test kits segment is forecast to reach US$7.2 billion by 2032, advancing at a CAGR of 16.1%. Testing services are expected to record stronger growth at a CAGR of 20.7% during the analysis period.

Regionally, the U.S. gene panel market was valued at US$1.2 billion in 2025. China is projected to expand at a CAGR of 17.2% and reach US$2.2 billion by 2032. The report also evaluates market developments across Canada, Japan, Germany, France, Italy, the United Kingdom, the rest of Europe, Asia-Pacific and the rest of the world.

Competitive Landscape

The report examines the competitive environment, geographic presence and strategic positioning of companies participating in the global gene panel market. Featured organizations include:

Domain Expert Insights

The analysis incorporates perspectives from specialists across industry, enterprise and academia, providing context beyond conventional secondary research. The report tracks early market signals emerging from expert discussions, company activity, conference sessions, keynote presentations, panel discussions, corporate disclosures, annual reports, institutional publications and other validated sources.

These insights connect developing signals with broader strategic market direction, helping identify the technologies, applications and competitive developments most likely to influence future growth. The report also extends beyond market-level analysis by examining the companies shaping the competitive environment.

Market share is assessed where it provides meaningful strategic value. Because competitive structures differ substantially by geography, the analysis considers major regional markets at a level of detail appropriate to their individual dynamics.

Report Benefits

The report addresses how the global gene panel market is expected to evolve through 2032, which segments are positioned for the strongest growth, how regional market shares may change and which companies are best placed to benefit from expanding demand for genomic diagnostics and personalized medicine.

Key Attributes

For more information about this report visit https://www.researchandmarkets.com/r/otyiyf

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.